Highlights
This phase I/II trial evaluated a fully oral triplet of twice-weekly ixazomib, pomalidomide, and dexamethasone in 50 patients with relapsed/refractory multiple myeloma (RRMM), most of whom had prior exposure to lenalidomide and bortezomib.
The recommended phase II dose (RP2D) was ixazomib 4 mg on days 1, 4, 8, and 11; pomalidomide 4 mg on days 1-14; and dexamethasone on the day of and after ixazomib in 21-day cycles.
At the RP2D, the overall response rate was 65.8%, with 28.9% of patients achieving at least a very good partial response (VGPR). Median progression-free survival reached 17.8 months, and median duration of response was 19.3 months.
Toxicity was predominantly hematologic and appeared manageable with dose modification and supportive care. The most frequent adverse events were neutropenia, thrombocytopenia, leukopenia, fatigue, and anemia.
Background
Relapsed and refractory multiple myeloma remains a therapeutically complex setting despite major advances in proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and, more recently, cellular therapies and bispecific antibodies. In everyday practice, however, treatment selection is not determined solely by efficacy. Route of administration, patient frailty, travel burden, access to infusion centers, prior drug exposure, and cumulative toxicities all shape real-world regimen choice.
Triplet combinations that integrate a proteasome inhibitor, an immunomodulatory agent, and dexamethasone have long represented a clinically active platform in myeloma. Yet many effective relapse regimens require parenteral administration, frequent clinic visits, or complex scheduling. An all-oral regimen has obvious appeal, especially for patients seeking to reduce time in clinic or for healthcare systems managing capacity constraints.
Ixazomib is the first oral proteasome inhibitor approved for multiple myeloma. Pomalidomide is a potent immunomodulatory drug with established activity in lenalidomide-exposed and lenalidomide-refractory disease. Combining these agents with dexamethasone creates a mechanistically rational, fully oral triplet. The current study by Nadeem and colleagues is therefore clinically relevant not only because it explores efficacy, but also because it tests whether a more intensive twice-weekly schedule of ixazomib can be safely paired with pomalidomide and dexamethasone in RRMM.
Study Design
Overall design
This was a phase I/II dose-escalation and expansion study of twice-weekly ixazomib plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. The study used 21-day treatment cycles.
Population
Fifty patients were enrolled. They had received a median of 2 prior lines of therapy, indicating a relapsed population that was pretreated but not overwhelmingly late-line. Prior exposure patterns are especially important for interpretation: 98.0% had received lenalidomide and 88.0% had received bortezomib. These data suggest the cohort was highly relevant to current clinical practice, where many patients reach relapse after standard frontline or early-relapse exposure to both an immunomodulatory agent and a proteasome inhibitor.
Treatment regimen
Ixazomib was administered on a twice-weekly schedule on days 1, 4, 8, and 11. Dose levels tested were 3 mg and 4 mg. Pomalidomide was given on days 1-14 at doses of 2 mg, 3 mg, or 4 mg. Dexamethasone was administered on the day of and after ixazomib at doses of 12 mg or 8 mg, consistent with a regimen designed to maintain anti-myeloma synergy while balancing tolerability.
Recommended phase II dose
The highest dose level investigated, ixazomib 4 mg plus pomalidomide 4 mg, was established as the RP2D.
Endpoints
The phase I portion focused on dose-limiting toxicities and identification of the RP2D. The phase II component evaluated anti-myeloma activity and tolerability. Reported efficacy outcomes included overall response rate, depth of response, duration of response, progression-free survival, and overall survival.
Key Findings
Dose intensity and treatment exposure
Patients received a median of 11 cycles, which is notable for an oral triplet in the relapsed/refractory setting. This level of exposure supports the authors’ conclusion that the regimen was feasible over time rather than only during early treatment cycles.
Safety and tolerability
The safety profile was dominated by hematologic toxicity. Across all 50 treated patients, neutropenia occurred in 76.0%, including grade 3 in 22.0% and grade 4 in 4.0%. Thrombocytopenia occurred in 70.0%, with grade 3 and grade 4 rates of 8.0% each. Leukopenia occurred in 68.0%, including grade 3 in 22.0%. Fatigue was reported in 52.0%, though grade 3 fatigue was uncommon at 4.0%. Anemia occurred in 46.0%, with grade 3 anemia in 2.0%.
During dose escalation, two dose-limiting toxicities were observed: one grade 3 upper respiratory tract infection and one grade 3 neutropenia. Importantly, the highest tested dose level still emerged as the RP2D, suggesting that toxicity, while common, remained manageable within the study framework.
Several practical observations follow from this safety pattern. First, the toxicities align with what clinicians would anticipate from pomalidomide-based therapy, particularly with respect to marrow suppression. Second, no unexpected safety signal is evident from the abstract. Third, because the regimen is fully oral, hematologic monitoring remains essential; convenience should not be confused with low-acuity management. In practice, this regimen would likely require careful blood count surveillance, infection counseling, and readiness to adjust doses or provide growth factor support according to institutional standards.
Efficacy in the overall population
Among all 50 patients, the overall response rate was 60.0%, and 24.0% achieved at least VGPR. These results are meaningful in a cohort with near-universal prior lenalidomide exposure and high prior bortezomib exposure. Median duration of response was 18.0 months, and median progression-free survival was 13.9 months. The reported 3-year overall survival rate was 85.2%.
Efficacy at the recommended phase II dose
In the 38 patients treated at the RP2D, efficacy appeared stronger. The overall response rate was 65.8%, and 28.9% achieved at least VGPR. Median duration of response was 19.3 months, and median progression-free survival was 17.8 months. The 3-year overall survival rate was 80.3%.
For clinicians, the progression-free survival signal is particularly notable. A median PFS approaching 18 months in an RRMM population with prior lenalidomide and bortezomib exposure suggests that this oral triplet may provide meaningful disease control, especially in patients who are not immediate candidates for antibody-based or cellular approaches, or in those for whom infusion frequency is a major barrier.
Interpreting the efficacy signal
Cross-trial comparisons should always be cautious, but the magnitude of benefit reported here appears clinically respectable for a phase I/II study in a pretreated RRMM population. The depth of response is moderate rather than transformative, yet the durability of response strengthens the clinical relevance of the regimen. The findings suggest a treatment option that may be more attractive for sustained disease control than for inducing exceptionally deep remissions.
Clinical Interpretation
Why this regimen matters
The main clinical value of this study lies in its demonstration that a fully oral triplet can deliver durable activity without introducing an obviously prohibitive toxicity burden. That point is increasingly important in myeloma, where treatment landscapes are rich but often operationally demanding. In many settings, patients cycle through therapies over years, and preserving quality of life and logistical simplicity is not a trivial advantage.
Ixazomib-based therapy has sometimes been viewed as convenient but less potent than some parenteral proteasome inhibitor combinations. This study argues that schedule and partner selection matter. Pairing twice-weekly ixazomib with pomalidomide may enhance anti-myeloma activity compared with more attenuated oral approaches, although confirmation in larger comparative trials would be needed before firm conclusions can be drawn.
Where this regimen may fit in practice
This regimen may be particularly relevant for patients with standard-risk RRMM who have previously received lenalidomide and bortezomib and need an outpatient, low-infusion-burden strategy. It may also appeal to patients in rural settings, older adults who prefer fewer hospital visits, and systems seeking alternatives when chair time or infusion resources are limited.
That said, the regimen’s place in therapy must now be judged against a much more crowded treatment environment than in earlier eras of myeloma relapse management. CD38 antibody-based triplets, selinexor-based combinations, CAR T-cell therapy, bispecific antibodies, and other later-generation approaches have expanded options considerably. As a result, the ixa-pom-dex combination is unlikely to displace more active immune-based therapies in eligible patients when those therapies are readily accessible. Its strongest niche may be as a practical, oral, bridgeable, and sustainable regimen rather than a maximal-intensity one.
Biologic rationale
The biologic rationale for combining a proteasome inhibitor with an immunomodulatory drug remains strong. Proteasome inhibition disrupts protein homeostasis in plasma cells, which are particularly vulnerable because of heavy immunoglobulin production. Immunomodulatory drugs, including pomalidomide, exert direct anti-myeloma effects while also modifying the tumor microenvironment and enhancing immune effector activity. Dexamethasone contributes cytoreduction and augments combination efficacy. In lenalidomide-exposed disease, pomalidomide offers a pharmacologically distinct and often still-active immunomodulatory option.
Strengths and Limitations
Strengths
The study has several strengths. It addresses a practical unmet need with a mechanistically coherent regimen. The patient population is clinically relevant because prior lenalidomide and bortezomib exposure was common. The reported duration of treatment and survival outcomes suggest that the regimen was not only active but sustainable. In addition, the phase I/II design appropriately established a usable RP2D before expansion.
Limitations
The main limitation is the absence of a randomized comparator. Without direct comparison against pomalidomide-dexamethasone alone, another ixazomib schedule, or an antibody-containing regimen, it is difficult to quantify the regimen’s incremental benefit. The sample size was small, as expected for an early-phase trial, which limits precision around efficacy and safety estimates and constrains subgroup analysis.
Interpretation is also affected by limited detail in the abstract regarding cytogenetic risk, refractoriness status, prior anti-CD38 exposure, reasons for treatment discontinuation, dose reductions, neuropathy incidence, and quality-of-life outcomes. Those variables are highly relevant when positioning a regimen in modern RRMM care. Finally, because the field has evolved rapidly, external validity will depend on how similar current patients are to those enrolled in the study.
Comparison With the Broader RRMM Landscape
Pomalidomide-dexamethasone is an established backbone in relapsed myeloma, and multiple triplets have been built upon it. Parenteral proteasome inhibitor combinations and monoclonal antibody combinations generally remain standards in many relapse settings because of strong efficacy data. However, those regimens may not always be ideal or feasible. The contribution of this trial is not merely another active triplet, but the demonstration that oral-only therapy can achieve respectable response depth and durability in a difficult disease state.
From a health-services standpoint, an effective oral regimen can improve flexibility of care delivery. For health systems, this may reduce infusion center dependence. For patients, it may lessen travel time and work disruption. For clinicians, it offers another option when treatment goals prioritize disease control, adherence feasibility, and maintenance of routine living. These benefits are meaningful, but they depend on robust patient education and monitoring because oral therapy shifts part of treatment execution from clinic to home.
Implications for Practice and Research
Clinically, this study supports twice-weekly ixazomib-pomalidomide-dexamethasone as a plausible option for selected patients with RRMM, especially those previously exposed to lenalidomide and bortezomib who prefer or require an all-oral regimen. The marrow toxicity profile suggests that patient selection and supportive care remain essential. Baseline blood counts, infection risk, prior tolerance of immunomodulatory agents, and ability to adhere to a 21-day schedule should all inform use.
Future studies should clarify which patients derive the greatest benefit. Randomized comparisons against pomalidomide-dexamethasone or other oral/low-burden triplets would help define true added value. Correlative studies exploring genomic risk, proteasome inhibitor sensitivity, and immune microenvironment features could identify predictive biomarkers. Quality-of-life and treatment-preference data would be especially valuable, because the principal distinguishing feature of this regimen is not only efficacy, but convenience.
As the myeloma field continues to move toward individualized sequencing, oral regimens such as this one may assume a strategic role: as interim therapy while awaiting cellular treatment, as a lower-burden relapse option in community practice, or as a bridge for patients not yet ready for intensive immune-based approaches.
Conclusion
The phase I/II study by Nadeem and colleagues indicates that twice-weekly ixazomib combined with pomalidomide and dexamethasone is an active and generally manageable all-oral regimen for relapsed/refractory multiple myeloma. At the RP2D, the regimen produced a 65.8% overall response rate, a median duration of response of 19.3 months, and a median progression-free survival of 17.8 months in a population heavily exposed to lenalidomide and bortezomib.
These findings do not by themselves redefine standard of care, but they do strengthen the case for oral triplets as a meaningful part of modern RRMM management. In an era of increasingly complex therapeutic choices, a regimen that combines efficacy, durability, and real-world feasibility deserves attention.
Funding and Clinical Trial Registration
The abstract provided does not report funding details or a ClinicalTrials.gov registration number. Readers should consult the full Haematologica publication or the PubMed record for complete trial administration and funding information.
References
1. Nadeem O, Redd RA, Barth PM, Bayliss TJ, Laubach JP, Bianchi G, Mo CC, Reagan JL, Midha S, Sperling AS, Liu Y, Hartley-Brown MA, Chuma MP, Nicholson T, Benjamin EJ, Distaso A, Regan E, Hof AMV, Dahill AJ, Goldbaum R, Mohammadi K, Lewis A, Poda R, Munshi NC, Anderson KC, Ghobrial IM, Richardson PG. A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Haematologica. 2026-05-28. PMID: 42206445.
2. Richardson PG, Attal M, Campana F, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107.
3. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811-1822.
4. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621-1634.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Current version available at NCCN.org.